Pharma
AlphaProteo was created to advance drug design and disease understanding by helping researchers configure high-strength proteins that bind to molecules.
The collaboration will leverage Genetic Leap's RNA-targeted AI platform to create genetic medicines against selected targets.
It enables the rapid monitoring of L-dopa levels, informing its optimal dosage adjustment.
QuantHealth cofounder and CEO Orr Inbar discusses how using artificial intelligence for clinical trial simulations can help solve challenges often seen by patients, researchers and the pharmaceutical industry when studying a new drug.
Waltz Health partners with Reliance Rx for specialty drug access, and Marshall Health Network and Primefocus Health collaborate on services for regional healthcare.
Sonny Shergill, vice president of commercial digital health at AstraZeneca, highlights pharma's perspective on digital health investments and partnerships for sector growth.
The Act is the world's first major law for AI implementation and provides regulations for high-risk applications of the technology, including its use in healthcare.
The company will use the funds to accelerate its growth, expand the use of its models for different conditions and open an office in Cambridge.
HIMSS24
Emmanuel Bilbault, cofounder and CEO of POSOS, says the company's AI-driven international drug database's use of medication codes enables it to cross-reference EHR data and tailor prescriptions to meet a patient's specific needs.
The company will use the funds to expand its workforce, including its sales team, in order to broaden its biopharma partnerships.